ACTINIUM PHARMACEUTICALS INC(DELAWARE)
ACTINIUM PHARMACEUTICALS INC(DELAWARE)
Aktie · US00507W2061 · ATNM · A2QA48 (XASE)
Übersicht Finanzkennzahlen
1,78 USD
-2,47 % -0,05 USD
AMEX (XNYS) · Aktuelle Kurse und Charts bei MoneyPeak
25.07.2025 19:59

Aktuelle Kurse von ACTINIUM PHARMACEUTICALS INC(DELAWARE)

BörseTickerWährungLetzter UmsatzKursTagesveränderung
XNYS: NYSE
NYSE
ATNM
USD
25.07.2025 19:59
1,78 USD
-0,07 USD
-3,53 %

Performance

Heute Woche Monat 3 Monate 6 Monate 1 Jahr 5 Jahre
0,00 % 1,43 % 7,58 % 39,22 % 36,54 % -77,53 % -88,88 %

Firmenprofil zu ACTINIUM PHARMACEUTICALS INC(DELAWARE) Aktie

Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company was incorporated in 2000 and is based in New York, New York.

Unternehmensdaten

Name ACTINIUM PHARMACEUTICALS INC(DELAWARE)
Firma Actinium Pharmaceuticals, Inc.
Symbol ATNM
Website https://www.actiniumpharma.com
Heimatbörse XASE AMEX
WKN A2QA48
ISIN US00507W2061
Wertpapierart Aktie
Sektor Healthcare
Branche Biotechnology
CEO Mr. Sandesh C. Seth M.B.A., M.S.
Marktkapitalisierung 54 Mio
Land Vereinigte Staaten von Amerika
Währung USD
Mitarbeiter 0,0 T
Adresse 275 Madison Avenue, 10016 New York City
IPO Datum 2012-12-27

Aktien-Splits

Datum Split
11.08.2020 1:30

Ticker Symbole

Name Symbol
Frankfurt 7AY1.F
NYSE ATNM

Weitere Aktien

Investoren die ACTINIUM PHARMACEUTICALS INC(DELAWARE) die halten, haben auch folgende Aktien im Depot:
FRONTIER COMMUNICTS 16/25
FRONTIER COMMUNICTS 16/25 Anleihe
LBBW ARRB BOA SZ 14/21
LBBW ARRB BOA SZ 14/21 Anleihe
Die Finanzplattform MoneyPeak trackt und analysiert Investitionen und Portfolios. Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Impressum Datenschutz Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025